Concern about the potential increased risk of cardiovascular
|
|
- Walter Osborne
- 5 years ago
- Views:
Transcription
1 Myocardial Infarction and Use of Low-Dose Oral Contraceptives A Pooled Analysis of 2 US Studies Stephen Sidney, MD, MPH; David S. Siscovick, MD, MPH; Diana B. Petitti, MD, MPH; Stephen M. Schwartz, PhD, MPH; Charles P. Quesenberry, PhD; Bruce M. Psaty, MD, PhD, MPH; Trivellore E. Raghunathan, PhD; Joseph Kelaghan, MD, MPH; Thomas D. Koepsell, MD, MPH Background Population-based case-control studies to assess the relationship of low-dose oral contraceptive (OC) use with myocardial infarction (MI) were performed at 2 sites in the United States (California and Washington state). The purpose of the present study was to estimate risk of MI in relation to use of low-dose OCs in a pooled analysis combining results from the 2 sites. Methods and Results The study included as cases women aged 18 to 44 years with incident MI who had no prior history of ischemic heart disease or cerebrovascular disease. Women in the case and control groups were interviewed in person regarding OC use and cardiovascular risk factors. The analysis included 271 MI cases and 993 controls. Compared with noncurrent users, the adjusted pooled odds ratio for MI in current OC users was 0.94 (95% CI, 0.44, 2.20) after adjustment for major risk factors and sociodemographic factors. Compared with never users, the adjusted pooled odds ratio for MI was 0.56 (0.21, 1.49) in current OC users and 0.54 (0.31, 0.95) in past OC users. Among past OC users, duration and recency of use were unrelated to MI risk as was current hormone replacement therapy. There was no evidence of interaction between OC use and age, presence of cardiovascular risk factors (hypercholesterolemia, hypertension, diabetes), obesity, or smoking. Conclusions We conclude that low-dose OCs as used in these populations are safe with respect to risk of MI in women. (Circulation. 1998;98: ) Key Words: women myocardial infarction epidemiology risk factors Concern about the potential increased risk of cardiovascular disease (CVD) associated with oral contraceptive (OC) use has existed since soon after the introduction of OCs in Although several 1 6 but not all 7 10 of the early studies showed evidence of increased risk of myocardial infarction (MI) with current OC use, these findings were based on the use of OCs containing higher doses of estrogen than those now commonly prescribed. More recent reports have generally shown modest ( 2-fold) increases in risk that were not statistically significant in current OC users, although an 5-fold increase in risk of MI in current OC users was shown in the study conducted by the World Health Organization (WHO). 16 Most studies have reported no increased risk of MI associated with past OC use, 1,2,4,16,17 although complete agreement on this issue is lacking. 5 In 1991, the National Institute of Child Health and Human Development funded population-based case-control studies at 2 sites (California and Washington state) to assess the relationship of low-dose OC use with MI. The study designs were developed independently by investigators at both sites with the expectation that key variables would be collected in a manner that would allow pooling of data. In a previous report 15 of the results of the Kaiser Permanente Medical Care Program (KPMCP) study in California, the odds ratio (OR) for MI was 1.67 (95% CI, 0.48, 5.85) in current OC users compared with noncurrent users; when compared with never users, OR was 1.14 (0.48, 4.72) for current OC users and 0.60 (0.25, 1.44) for past users. The results of the University of Washington (UW) study have not previously been published. The primary purposes for a pooled analysis of the data of the 2 studies were to determine whether the OR for MI associated with current OC use was consistent between the 2 study sites; to obtain a higher degree of precision in estimating the OR for MI associated with OC use than could be achieved at either Received January 14, 1998; revision received May 5, 1998; accepted May 10, From the Division of Research, Kaiser Permanente Medical Care Program, Northern California, Oakland (S.S., C.P.Q.); Cardiovascular Health Research Unit (D.S.S., S.M.S., B.M.P., T.D.K.), Department of Epidemiology, School of Public Health and Community Medicine (D.S.S, S.M.S., B.M.P., T.D.K), Division of General Internal Medicine, Department of Medicine, School of Medicine (D.S.S.), and Department of Biostatistics, School of Public Health and Community Medicine (T.E.R.), University of Washington, Seattle; Research and Evaluation, Kaiser Permanente Medical Care Program, Southern California, Pasadena (D.B.P.); and the Contraceptive and Reproductive Evaluation Branch, National Institute of Child Health and Human Development, Bethesda, Md (J.K.). Dr Raghunathan is now at the Department of Biostatistics, University of Michigan, Ann Arbor. Correspondence to Stephen Sidney, MD, MPH, Kaiser Permanente Division of Research, 3505 Broadway, Oakland, CA sxs@dor.kaiser.org 1998 American Heart Association, Inc. 1058
2 Sidney et al September 15, study site alone; and to determine whether the apparent protective effect of past OC use found in the Kaiser Permanente (KP) study was also present in the UW study and, if so, to perform analyses to attempt to better understand this association. Methods Case Identification All MIs occurring among 18- to 44-year-old female members of the KPMCP were identified from May 1991 to August 1994 (northern California) and from July 1991 to August 1994 (southern California). For the UW study, incident MIs were identified from July 1991 through February 1995 among women aged 18 to 44 years who lived in King, Pierce, and Snohomish counties. In both studies, the medical record for each potential case was reviewed to establish the diagnosis of MI with diagnostic criteria adapted from those of the Cardiovascular Health Study. 18 Included as cases were women with events classified as definite or probable MI on the basis of chest pain (presence or absence), cardiac enzymes, and ECG findings. Women with a history of coronary heart disease (CHD) or cerebrovascular disease before the date of identification by the study were excluded. All women identified as cases in the KP study were required to have been admitted to the hospital or seen in the emergency department, whereas the UW study also included subjects who died of primary cardiac arrest outside the hospital; these subjects (n 16) were excluded from the pooled analysis. Proxy interviews were conducted with a close relative or friend when the women with MI died or were unable to communicate orally. Concerns about the accuracy of data on past OC use led to the exclusion of proxy interview data (n 26) from the pooled analysis. Control Identification For each woman with MI in the KP study, 3 controls, matched for year of birth and location of care facility, were randomly selected from female members of the KPMCP. Controls who could not be located, declined to be interviewed, or spoke neither English nor Spanish were replaced with other randomly selected controls until 3 controls had been enrolled for each women with MI or 2 replacement controls had been selected. The control group for the UW study contained women who served as a common control group for the study of the relationship of OC use to MI and a concomitant study of stroke. A representative sample of female residents of King, Pierce, or Snohomish counties, frequency matched to the combined age distribution of cases for the studies of MI and stroke, was selected during the case diagnosis period by random-digit telephone dialing. Interviews For both studies, eligible cases and controls were interviewed in person by trained interviewers who used a standardized instrument. Informed consent was obtained in person before the interview. All information was collected for the period before a predefined reference date, which was the date of MI for cases. For controls, the reference date was either the same date as the case to which she was matched (KP) or a randomly assigned date selected from among the possible MI diagnosis dates (UW). In the KP study, a woman was considered a current OC user if she reported that she was taking OCs in the month before the reference date. In the UW study, OC use was ascertained according to responses given in calendar months with current OC use defined as use of OCs in either the same calendar month as the reference date or the calendar month before the reference date. In each study, a woman was classified as a past OC user if she had ever used OCs but did not meet the current user definition. All other women were classified as never users of OCs. While the interview instruments were not identical, comparable self-reported data were obtained for key analytic variables, including history of OC use, sociodemographic characteristics, obstetrical and gynecological history, and medical and lifestyle cardiovascular risk factors. Statistical Methods The exposure OR was used to estimate relative risk. The pooled analysis accounted for the difference in design of control selection strategies at the 2 study sites by an adaptation of logistic regression. 19 Estimation of pooled ORs was accomplished by the method of maximum likelihood with the contribution to the likelihood function from the matched case-control study (KP) assessed by conditional logistic regression and the contribution from the unmatched study (UW) assessed by unmatched logistic regression. Interval estimation as well as tests of significance were accomplished with standard large-sample likelihood theory. The combined sample size of 271 cases and 993 controls provided approximately 90% power to detect an OR of 2.0 with a 2-sided test and significance level of Tests of heterogeneity across study sites in the effects of confounders and exposure were performed with Wald s 2 test for equality of the regression coefficients for the 2 sites. All computations were performed with software developed in the GAUSS programming language. 20 We adjusted for race/ethnicity and major established risk factors for CHD, including cigarette smoking, hypertension, hypercholesterolemia, and diabetes. In addition, we adjusted for variables that were apparent confounders in these data, ie, if there was an appreciable change ( 5%) in the exposure coefficients with the addition of the potential confounder. Appropriate cross-product terms were included in the models to test for the statistical significance of potential interactions and to obtain stratum-specific estimates of association between current OC use and MI. Results Case Identification A total of 187 incident confirmed MIs occurred in women aged 18 to 44 years who were members of the KPMCP during the period of case ascertainment. One was not eligible for interview because she did not speak English or Spanish. Interviews were completed for 178 (95.7%) of the remaining 186 cases or their proxies; reasons for nonparticipation included physician refusal (n 1) or patient refusal (n 7). Data from 11 of the interviews were excluded (Table 1), leaving 167 cases for analysis. A total of 192 eligible patients were identified in the UW catchment area (excluding the 16 out-of-hospital deaths). Interviews were completed for 126 (65.6%) of the 192 cases; reasons for nonparticipation included physician refusal (n 4), patient or proxy refusal (n 46), inability to locate patient or proxy (n 14), and inability to interview patient before close of fieldwork (n 2). Data from 22 cases were excluded (Table 1), leaving 104 cases for analysis. TABLE 1. by Study Distribution of MI Cases by Inclusion Status Kaiser Permanente University of Washington Total interviewed Not included in analysis No direct interview 7 19 Missing data* 1 1 Pregnant at reference date 3 2 Included in analysis *Whether or not the woman was a current, past, or never user of OCs.
3 1060 MI and Low-Dose Oral Contraceptives TABLE 2. Characteristics of MI Cases and Controls by OC Use: Combined Sites Controls by OC Use Status Cases (n 271) Control Identification Seventy-seven percent of all KP controls were selected from the initially chosen 3 controls, and 95.5% of the interviewed case-control sets had 3 controls. Altogether, of the eligible women identified for the KP study, an attempt was made to enroll 758, of whom 7 were excluded because of prior history of major CVD (n 1), inability to speak English or Spanish (n 3), or database error in age, gender, or address (n 3). Of the remaining 751 women, 545 were interviewed for an overall response rate of 72.6%. Of the 492 controls in the matched sets for the 167 cases included in this analysis, 11 were excluded because of pregnancy, leaving 481 controls in the analysis set. In the UW study, a household census to ascertain women meeting eligibility criteria was completed for 94.9% of the residences contacted during the random-digit dialing for control identification. Among the eligible women identified, an attempt was made to enroll 691, frequency matched to the combined age distribution of all MI and stroke patients recruited for the study. Seven of the 691 women were excluded because of prior history of major CVD (n 6) or inability to communicate in English (n 1). Of the remaining 684 women, 526 were interviewed for an estimated overall response rate of 73.0% (526/ %). Of the 526 controls interviewed, 14 were Never (n 136) Past (n 770) Current (n 87) All Controls (n 993) Age, y [mean (SD)] 39.7 (4.8) 38.6 (5.1) 39.5 (4.5) 32.9 (6.5) 38.8 (5.1) BMI* [mean (SD)] 30.1 (7.3) 26.2 (6.2) 25.6 (5.8) 24.1 (4.4) 25.5 (5.8) Months of OC use [mean (SD)] 49.8 (48.4) (49.3) (70.4) 58.1 (54.5) Parity [mean (SD)] 1.9 (1.4) 1.5 (1.5) 2.0 (3.7) 0.9 (1.0) 1.8 (3.4) Current/occasional smoker, % Alcohol never/occasional, % Heavy exercise 2 4 times/wk, % Treated HBP, % Treated DM, % Treated high cholesterol, % Current OC user, % Ever OC use, % College, % Ethnicity, % Asian White, non-hispanic Black Hispanic Married/living as married, % Menopausal, % Hysterectomy, % No ovaries, % HBP indicates high blood pressure, and DM, diabetes mellitus. *BMI equals weight (kg) divided by square of height (m 2 ). Use in the month before index date. excluded because of pregnancy as of their reference date, leaving 512 controls in the analysis set. Table 2 shows the characteristics of the MI cases and controls overall and stratified by OC use status. Controls were unlikely to be treated for hypertension or diabetes regardless of OC use status, and treatment for high cholesterol among controls was very rare. Current and former OC users were more likely to be smokers than never users. Younger age and white race/ethnicity were associated with current use. Former use was associated with frequent heavy exercise, education less than college graduation, and being married or living as married. The age-race/ethnicity adjusted OR for MI in current OC users was 0.55 (95% CI, 0.27, 1.12) compared with noncurrent users. The fully adjusted OR for MI was 0.94 (0.40, 2.20) in current compared with noncurrent users and adjusted for age, treated hypertension, treated diabetes, smoking, race/ ethnicity, body mass index (BMI), education, and menopause (Table 3). When current users of OCs were compared with never users, the age-race/ethnicity adjusted OR for MI was 0.45 (0.20, 0.99) and the fully adjusted OR was 0.56 (0.21, 1.49) (Table 3). The OR tended to decrease with increasing duration of use in current OC users compared with both noncurrent users and never users (Table 4), although the test for trend was not statistically significant.
4 Sidney et al September 15, TABLE 3. Adjusted * Odds Ratio for MI in Relation to Current and Past Use of Low-Dose OCs Kaiser Permanente Washington Pooled Data Characteristic Case/Controls, n OR (95% CI) Case/Controls, n OR (95% CI) Case/Controls, n OR (95% CI) Current vs noncurrent use Not current use 158/ (...) 97/ (...) 255/ (...) Current use 8/ (0.33, 4.04) 4/ (0.20, 2.27) 12/ (0.40, 2.20) , 1 df, P Current and Past vs never use Never use 26/ (...) 15/ (...) 41/ (...) Current use 8/ (0.18, 2.89) 4/ (0.10, 1.62) 12/ (0.21, 1.49) Past use 132/ (0.26, 1.18) 82/ (0.22, 1.26) 214/ (0.31, 0.95) , 2 df, P *Adjusted for age, treated hypertension (yes/no), treated diabetes (yes/no), smoking (current, occasional/past), race/ethnicity (Hispanic/black/Asian/other/white), BMI (continuous), education, and menopause. Use in the month before index date. Test of heterogeneity of adjusted regression coefficients for OC use. The age-race/ethnicity adjusted OR for MI was 0.79 (0.53, 1.17) in past OC users compared with never users, and the fully adjusted OR was 0.54 (0.31, 0.95). Among past OC users, duration and recency of past OC use were essentially unrelated to risk of MI (Table 4). The adjusted OR for MI was 1.02 (0.42, 2.47) in past users of OCs who were currently receiving hormone replacement therapy (HRT) compared with never users. We also examined ORs for MI in women 40 years old and 40 years old, in women with and without major TABLE 4. Adjusted Pooled Odds Ratios in Relation to Duration of Current and Past OC Use and Recency of Past OC Use Characteristic Cases/Controls, n OR* (95% CI) Duration of OC use in current users, y Referent: not current 255/ (...) 4 5/ (0.45, 9.16) 5 9 5/ (0.44, 5.78) 10 2/ (0.07, 1.73) Referent: never 41/ (...) 4 5/ (0.27, 6.09) 5 9 5/ (0.24, 3.72) 10 2/ (0.04, 1.10) Duration of OC use in past users, y Referent: never 41/ (...) 1 62/ (0.32, 1.22) / (0.21, 0.72) / (0.37, 1.51) 10 21/ (0.29, 1.44) Recency of past use, y Referent: never 41/ (...) 1 4/ (0.18, 2.92) / (0.26, 1.78) / (0.23, 1.07) / (0.29, 0.91) *Adjusted for age, treated hypertension, treated diabetes, smoking, race/ ethnicity, BMI, education, and menopause Use in the month before index date. cardiovascular risk factors (hypertension, high cholesterol, and diabetes), in obese and nonobese women, in women who were current cigarette smokers and those who were not, and according to progestin use (Table 5). Stratum-specific ORs were close to 1, and there was no evidence of interaction between OC use and age (P 0.28), risk factor presence (P 0.75), obesity (P 0.81), or smoking (P 0.93). The ORs for current OC preparations containing a progestin derived from 19-nortestosterone (ie, norethindrone family) TABLE 5. Adjusted Pooled Odds Ratios of MI for Current OC Use Relative to Noncurrent Use and Stratified by Selected Variables Current Users/Total, n Cases Controls OR (95% CI) Age* y 40 10/91 69/ (0.45, 3.26) 40 2/180 18/ (0.06, 2.67) Risk factors Present 2/82 4/ (0.03, 11.88) Not present 10/189 83/ (0.40, 2.33) Smoking Current smoker 6/165 12/ (0.33, 2.54) Not current smoker 6/106 75/ (0.27, 3.55) Obesity BMI 27.3 kg/m 2 5/153 17/ (0.29, 3.80) BMI 27.3 kg/m 2 7/115 70/ (0.33, 2.36) Progestin* Norethindrone family (0.37, 2.86) Norgestrel family (0.19, 6.57) *Adjusted for age, treated hypertension, treated diabetes, treated/diagnosed high cholesterol, smoking, race/ethnicity, BMI, education, and menopause. Risk factors are high blood pressure, high blood cholesterol, and diabetes. Adjusted for age, smoking, race/ethnicity, BMI, education, and menopause. Adjusted for age, treated hypertension, treated diabetes, treated/diagnosed high cholesterol, race/ethnicity, BMI, education, and menopause. Adjusted for age, treated hypertension, treated diabetes, treated/diagnosed high cholesterol, smoking, race/ethnicity, education, and menopause.
5 1062 MI and Low-Dose Oral Contraceptives and those containing a progestin derived from gonane (ie, norgestrel family) were not different (Table 5). Most current OC users (9 of 12 cases, 78 of 87 controls) used formulations containing 50 g of ethinyl estradiol. Of the remaining 3 cases and 9 controls, 7 (2 cases, 5 controls) used 50- g preparations, and the estrogen dose of the other 5 preparations was unknown (1 case, 4 controls). The adjusted OR for current OC preparations containing 50 g was 0.69 (0.26, 1.86) for current compared with noncurrent users of OCs and 0.41 (0.14, 1.24) for current users of OCs compared with never users. Discussion The OC findings in relation to risk of MI were reasonably consistent in the KP and UW studies. In the pooled analysis, there was no evidence of an increase in risk of MI associated with use of OCs. As anticipated, combining the data from the 2 studies narrowed the 95% CI for the relative odds of MI associated with current OC use compared with either study alone. The pooled OR for current use relative to noncurrent use had an upper limit of 2.2, virtually ruling out a larger effect of current OC use. The results are consistent with most other recent studies, which have not shown statistically significant elevations in risk of MI associated with current OC use Although the WHO study 16 found an 5-fold increased risk of MI associated with current OC use, the authors concluded that the increased risk probably reflects more frequent use of OCs by women with other cardiovascular risk factors and less screening than is currently carried out in the United States. In particular, in the WHO study, there was no increased risk of MI associated with OC use among nonsmoking women at low risk who had a blood pressure check before taking OCs. Past use of OCs was associated with a statistically significant decrease in risk of MI in the pooled analysis of KP and UW data, and the ORs for the 2 sites were nearly identical. Possible explanations for this apparent protective association, if not a chance finding, include selection bias, unmeasured confounding, and a true protective effect. Selection bias could occur if past users of OCs were prescribed OCs only if they were at low risk for heart disease. However, our data (Table 2) did not suggest that controls who were past OC users had lower levels of major cardiovascular risk factors than never users. However, it is possible that past users and never users differed in unmeasured potential confounders such as diet. A true protective effect of past OC use might also result from beneficial effects on lipids. Although earlier generations of OCs had adverse effects on lipids and lipoproteins, 21 some newer formulations of progestin may have beneficial effects on LDL and HDL cholesterol. 22 In the absence of knowledge of variations of OC formulations used in the past by study cohort members, we cannot make definitive statements about likely effects on lipids and other cardiovascular risk factors. The absence of variation in the effect of OCs in relation to duration or recency of use is evidence against a biologically mediated protective mechanism. The lack of association of current HRT with risk of MI in past OC users compared with never users suggests that HRT use did not explain the decreased risk of MI associated with past OC use. There was no evidence of interaction between current OC use and cigarette smoking in contrast with earlier studies performed when higher-dose OCs were commonly used. These studies showed higher risks of MI associated with OC use in smokers than in nonsmokers. 12,23 The previously reported KP analysis showed no evidence of an interaction between OC use and smoking on risk of MI, 15 and most other studies performed as low-dose OC use became common have been unable to address this issue. 11,13,14 However, the WHO study showed marked elevations in risk of MI among smokers. 16 The discrepancy between the results of the WHO study and these pooled US studies may reflect unmeasured hypertension among smokers in the WHO study or other unmeasured differences in the health of smokers in these studies. Limitations of this study include possible response, recall, and diagnostic bias. Because recall bias is more likely to result in a greater propensity for reporting exposure by cases compared with controls, its presence would result in an RR that is higher than the true value. Diagnostic bias would occur if diagnosis of MI is more likely to be considered by clinicians in a woman using OCs than in nonusers and also would result in an RR higher than the true value. The use of standardized diagnostic criteria make it unlikely that there was bias in the evaluation of cases. The KP study did not perform surveillance for fatal MIs, whereas in the UW study, 42 cases had died by initiation of recruitment. There is a potential bias in this study if OC use was related to more serious MIs resulting in early mortality. In particular, this might explain the lower risk associated with past OC use in this study, although results were similar in the only prospective study analyzing risk of CVD associated with past OC use. 17 Unmeasured potential confounders such as diet that might differ between cases and controls also create potential bias. Other limitations of this study include the small number of OC users who smoked, had other risk factors for CVD, and were 40 years old. Therefore, the study did not have adequate numbers to offer definitive statements regarding these and other issues (eg, race/ethnicity) relating to potential interactions. Although caution must always be exercised in generalizing the results of epidemiological studies, the results of this pooled analysis are reassuring in that they reinforce findings from other published studies of little or no increased risk of MI in users of low-dose OCs as taken in these settings. The possible protective association found for past OC users was not the result of HRT and remains unexplained. We conclude that low-dose OC use is safe in relation to risk of MI for healthy women without major CVD risk factors. Acknowledgments This work was supported by the National Institute of Child Health and Human Development, contract numbers N01-HD and N01-HD References 1. Mann JI, Vessey MP, Thorogood M, Doll R. Myocardial infarction in young women with special reference to oral contraceptive practice. BMJ. 1975;2:
6 Sidney et al September 15, Mann JI, Inman WHW. Oral contraceptives and death from myocardial infarction. BMJ. 1975;2: Jick H, Dinan B, Rothman KJ. Oral contraceptives and nonfatal myocardial infarction. JAMA. 1978;239: Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Oral contraceptive use in relation to nonfatal myocardial infarction. Am J Epidemiol. 1980;111: Slone D, Shapiro S, Kaufman DW, Rosenberg L, Miettinen OS, Stolley PD. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med. 1981;305: Adam SA, Thorogood M, Mann JI. Oral contraception and myocardial infarction revisited: the effects of new preparations and prescribing patterns. Br J Obstet Gynaecol. 1981;88: Inman WHW, Vessey MP. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of childbearing age. BMJ. 1968;2: Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. BMJ. 1969;2: Maguire MG, Tonascia J, Sartwell PE, Stolley PD, Tockman MS. Increased risk of thrombosis due to oral contraceptives: a further report. Am J Epidemiol. 1979;110: Krueger DE, Ellenberg SS, Bloom S, Calkins BM, Maliza C, Nolan DC, Phillips R, Rios JC, Rosin I, Shekelle RB, Spector KM, Stadel BV, Stolley PD, Terris M. Fatal myocardial infarction and the role of oral contraceptives. Am J Epidemiol. 1980;111: Rosenberg L, Palmer JR, Lesko SM, Shapiro S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol. 1990;131: Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners oral contraception study. BMJ. 1989;298: Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Br J Obstet Gynaecol. 1991;98: D Avanzo B, La Vecchia C, Negri E, Parazzini F, Franceschi S. Oral contraceptive use and risk of myocardial infarction: an Italian case-control study. J Epidemiol Community Health. 1994;48: Sidney S, Petitti DB, Quesenberry CP Jr, Klatsky AL, Ziel HK, Wolf S. Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynecol. 1996;88: WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet. 1997;349: Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med. 1988;319: Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, Cruise RG, Theroux S. Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol. 1995;5: Moreno V, Martin ML, Bosch FX, Sanjose S, Torres F, Munoz N. Combined analysis of matched and unmatched case-control studies: comparison of risk estimates from different studies. Am J Epidemiol. 1996; 143: Abtech Systems. The GAUSS System Version 3.1. Maple Valley, Wash: Abtech Systems, Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med. 1981;305: , Godsland I, Crook D, Wynn V. Coronary heart disease risk markers in users of low-dose oral contraceptives. J Reprod Med. 1991;36(suppl): Rosenberg L, Kaufman DW, Helmrich SP, Miller DR, Stolley PD, Shapiro S. Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA. 1985;253:
STROKE IN USERS OF LOW-DOSE ORAL CONTRACEPTIVES. The New England Journal of Medicine
STROKE IN USERS OF LOW-DOSE ORAL CONTRACEPTIVES DIANA B. PETITTI, M.D., STEPHEN SIDNEY, M.D., ALLAN BERNSTEIN, M.D., SHELDON WOLF, M.D., CHARLES QUESENBERRY, PH.D., AND HARRY K. ZIEL, M.D. ABSTRACT Background
More informationRISK OF ISCHEMIC STROKE ASSOCIATED WITH LOW-DOSE ORAL CONTRACEPTIVE USE: A META-ANALYSIS
RISK OF ISCHEMIC STROKE ASSOCIATED WITH LOW-DOSE ORAL CONTRACEPTIVE USE: A META-ANALYSIS Dae Hyun Kim, MD, MPH 1, Joachim Bleys, MD, MPH 2, Marlis Gonzalez-Fernandez, MD 3, Rebecca Gottesman, MD 4 and
More informationRisk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study
British Journal of Obstetrics and Gynaecology August 1998, Vol. 105, pp. 896896 Risk of myocardial infarction, angina and stroke in users of oral contraceptives: an updated analysis of a cohort study Jonathan
More informationCurrent Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes
Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes The Northern California Kaiser Permanente Diabetes Registry, 1995 1998
More informationDiabetologia 9 Springer-Verlag 1992
Diabetologia (1992) 35:967-972 Diabetologia 9 Springer-Verlag 1992 Oral contraceptive use and the risk of Type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women E. B. Rimm,
More informationDownloaded from jarums.arums.ac.ir at 22:00 IRDT on Friday March 22nd 2019
ﻣ Research & Scientific Journal of Ardabil University of Medical Sciences & Health Services Vol 2, No 8, Jun-Sep 2003 ﺳﻜﺘﻪ ) ( ﺧﻄﺮ ﻣﺨﺘﻠﻒ ﺷﺎﻣﻞ ﻗﺮ ﻧﺴﺨﻪ SPSS ﻳﺎﻓﺘﻪ ﻫﺎ (OR=٥/٤ %٥ CI=/ -٥/) ﺣﺎﺻﻞ ﺷﺪ p=٠/٠٥ (
More informationOriginal Contributions. Risk of Ischemic Stroke Among Users of the Oral Contraceptive Pill. The Melbourne Risk Factor Study (MERFS) Group
Original Contributions Risk of Ischemic Stroke Among Users of the Oral Contraceptive Pill The Melbourne Risk Factor Study (MERFS) Group Sasitorn Siritho, MD; Amanda G. Thrift, PhD; John J. McNeil, PhD;
More informationORIGINAL INVESTIGATION. Risk of Stroke in Women Exposed to Low-Dose Oral Contraceptives
Risk of Stroke in Women Exposed to Low-Dose Oral Contraceptives A Critical Evaluation of the Evidence ORIGINAL INVESTIGATION Wee-Shian Chan, MD, FRCPC, MSc; Joel Ray, MD, FRCPC, MSc; Eugene K. Wai, MD;
More informationAmerican Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease
American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease AMWA is a leader in its dedication to educating all physicians and their patients about heart disease,
More informationA prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women
CONTRACEPTION A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women Karen L. Margolis, M.D., a Hans-Olov Adami, M.D., b Juhua Luo, M.S., b Weimin Ye, M.D.,
More informationElevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes FRANK B. HU, MD 1,2,3 MEIR J. STAMPFER,
More informationORIGINAL INVESTIGATION. Hormone Replacement Therapy and Associated Risk of Stroke in Postmenopausal Women
ORIGINAL INVESTIGATION Hormone Replacement Therapy and Associated Risk of Stroke in Postmenopausal Women Rozenn N. Lemaitre, PhD, MPH; Susan R. Heckbert, MD, PhD; Bruce M. Psaty, MD, PhD; Nicholas L. Smith,
More informationEditorial. Smoking, Estrogen, and Prevention of Heart Disease in Women
Editorial Smoking, Estrogen, and Prevention of Heart Disease in Women Despite the remarkable decline in mortality rates from coronary heart disease (CHD) in the United States (and many other Western nations),
More informationWellness Coaching for People with Prediabetes
Wellness Coaching for People with Prediabetes PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY Volume 12, E207 NOVEMBER 2015 ORIGINAL RESEARCH Wellness Coaching for People With Prediabetes: A Randomized Encouragement
More informationRisk of venous thromboembolism in users of non-oral contraceptives Statement from the Faculty of Sexual and Reproductive Healthcare
Risk of venous thromboembolism in users of non-oral contraceptives Statement from the Faculty of Sexual and Reproductive Healthcare New data A paper published in May 2012 in the British Medical Journal
More informationStrategies for data analysis: case-control studies
Strategies for data analysis: case-control studies Gilda Piaggio UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction World Health Organization
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1997, by the Massachusetts Medical Society VOLUME 336 J UNE 19, 1997 NUMBER 25 POSTMENOPAUSAL HORMONE THERAPY AND MORTALITY FRANCINE GRODSTEIN, SC.D., MEIR
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationModelling Reduction of Coronary Heart Disease Risk among people with Diabetes
Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made
More informationHEALTH PROMOTION AND CHRONIC DISEASE PREVENTION PROGRAM OREGON STATE OF THE HEART AND STROKE REPORT 2001 PREPARED BY.
OREGON STATE OF THE HEART AND STROKE REPORT 2001 PREPARED BY THE OREGON DEPARTMENT OF HUMAN SERVICES HEALTH SERVICES HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION PROGRAM www.healthoregon.org/hpcdp Contents
More informationRESEARCH. Susan S Jick, director and senior epidemiologist Rohini K Hernandez, epidemiologist
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United
More informationStatus Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2
TABLE OF CONTENTS Status Update on the National Cardiovascular Prevention Guidelines 1 Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk 1-4 P&T Committee Formulary Action 5 Status
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationIs Alcohol Use Related To High Cholesterol in Premenopausal Women Aged Years Old? Abstract
Research imedpub Journals http://www.imedpub.com/ Journal of Preventive Medicine DOI: 10.21767/2572-5483.100024 Is Alcohol Use Related To High Cholesterol in Premenopausal Women Aged 40-51 Years Old? Sydnee
More informationObservational Study Designs. Review. Today. Measures of disease occurrence. Cohort Studies
Observational Study Designs Denise Boudreau, PhD Center for Health Studies Group Health Cooperative Today Review cohort studies Case-control studies Design Identifying cases and controls Measuring exposure
More informationCOMPARED WITH PLACEBO,
IGINAL INVESTIGATION Esterified Estrogen and Conjugated Equine Estrogen and the Risk of Incident Myocardial Infarction and Stroke Rozenn N. Lemaitre, PhD, MPH; Noel S. Weiss, MD, DrPH; Nicholas L. Smith,
More informationGeneral practice. Abstract. Subjects and methods. Introduction. examining the effect of use of oral contraceptives on mortality in the long term.
Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners oral contraception study Valerie Beral, Carol Hermon, Clifford
More informationFinancial Conflicts of Interest
Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine
More information2. Studies of Cancer in Humans
346 IARC MONOGRAPHS VOLUME 72 2. Studies of Cancer in Humans 2.1 Breast cancer 2.1.1 Results of published studies Eight studies have been published on the relationship between the incidence of breast cancer
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationRisk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study. Oral Contraceptives and the Risk of Ischemic Stroke
Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study Oral Contraceptives and the Risk of Ischemic Stroke Jeanet M. Kemmeren, PhD; Bea C. Tanis, MD; Maurice A.A.J. van den Bosch,
More informationEstrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence 1,2
IJE vol.33 no.3 International Epidemiological Association 2004; all rights reserved. International Journal of Epidemiology 2004;33:445 453 Advance Access publication 27 May 2004 DOI: 10.1093/ije/dyh125
More informationUse of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
open access Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the and databases Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox Division of
More informationcoronary heart disease (CHD) is the leading
Appendix I: Evidence on HRT and Coronary Heart Disease I coronary heart disease (CHD) is the leading cause of death among U.S. women, surpassing the rates from cancer and other diseases (13). Any change
More informationDoes low dose contraceptive pills increase stroke rate? A cross sectional study in North-West Iran
Original Article Does low dose contraceptive pills increase stroke rate? A cross sectional study in North-West Iran Mehdi Farhoudi 1, Ehsan Sharifipour 2, Hormoz Ayromlou 3, Saeed Charsouei 4, Elyar Sadeghihokmabadi
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationAnne H. Calhoun, MD, FAHS Professor of Anesthesiology Professor of Psychiatry
Combined Hormonal Contraceptives & Migraine with Aura Anne H. Calhoun, MD, FAHS Professor of Anesthesiology Professor of Psychiatry University of North Carolina Partner/Co-Founder Carolina Headache Institute
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationAppendix H: Evidence on HRT and Gallbladder Disease H
Appendix H: Evidence on HRT and Gallbladder Disease H T here are several theoretical reasons to expect a causal link between estrogens and gallbladder disease. In particular, estrogens increase the risk
More informationATTENTION-DEFICIT/HYPERACTIVITY DISORDER, PHYSICAL HEALTH, AND LIFESTYLE IN OLDER ADULTS
CHAPTER 5 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER, PHYSICAL HEALTH, AND LIFESTYLE IN OLDER ADULTS J. AM. GERIATR. SOC. 2013;61(6):882 887 DOI: 10.1111/JGS.12261 61 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER,
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationDevelopment, validation and application of risk prediction models
Development, validation and application of risk prediction models G. Colditz, E. Liu, M. Olsen, & others (Ying Liu, TA) 3/28/2012 Risk Prediction Models 1 Goals Through examples, class discussion, and
More informationrisk factors for stroke and myocardial infarction in women alone is therefore needed to provide a complete population as a whole.
Br Heart J 1989;61:403-9 Risk factors for stroke and myocardial infarction in women in the United Kingdom as assessed in general practice: a case-control study S G THOMPSON,* G GREENBERG,t T W MEADE From
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Understand goal of measurement and definition of accuracy Describe the threats to causal
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bucholz EM, Butala NM, Ma S, Normand S-LT, Krumholz HM. Life
More informationwho quit cigarette smoking
Rapid reduction in coronary risk for those who quit cigarette smoking Patrick McElduff and Annette Dobson Department of Statistics, University of Newcastle, New South Wales Robert Beaglehole and Rodney
More informationExperimental Design. Terminology. Chusak Okascharoen, MD, PhD September 19 th, Experimental study Clinical trial Randomized controlled trial
Experimental Design Chusak Okascharoen, MD, PhD September 19 th, 2016 Terminology Experimental study Clinical trial Randomized controlled trial 1 PHASES OF CLINICAL TRIALS Phase I: First-time-in-man studies
More informationStatins and newly diagnosed diabetes
DOI:10.1111/j.1365-2125.2004.02142.x British Journal of Clinical Pharmacology Statins and newly diagnosed diabetes Susan S. Jick & Brian D. Bradbury Boston Collaborative Drug Surveillance Program, 11 Muzzey
More informationPostmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationThe Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP
The Healthy User Effect: Ubiquitous and Uncontrollable S. R. Majumdar, MD MPH FRCPC FACP Professor of Medicine, Endowed Chair in Patient Health Management, Health Scholar of the Alberta Heritage Foundation,
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationSupplementary Table 4. Study characteristics and association between OC use and endometrial cancer incidence
Supplementary Table 4. characteristics and association between OC use and endometrial cancer incidence a Details OR b 95% CI Covariates Region Case-control Parslov, 2000 (1) Danish women aged 25 49 yr
More informationI t is established that regular light to moderate drinking is
32 CARDIOVASCULAR MEDICINE Taking up regular drinking in middle age: effect on major coronary heart disease events and mortality S G Wannamethee, A G Shaper... See end of article for authors affiliations...
More informationFatal primary malignancy of brain. Glioblasatoma, histologically
TABLE 10.2 TBI and Brain Tumors Reference Study Design Population Type of TBI Health s or Annegers et al., 1979 Burch et al., 1987 Carpenter et al., 1987 Hochberg et al., 1984 Double cohort All TBI in
More informationPostmenopausal Estrogens and Risk of Myocardial Infarction in Diabetic Women NICHOLAS L. SMITH, PHD KATHERINE M. NEWTON, PHD BRUCE M.
E p i d e m i o I o g y / H e a 11 h S e r v i c e s / P s y c h o s o c i a I R e s e a r c h N A L A R T I C L E Postmenopausal Estrogens and Risk of Myocardial Infarction in Diabetic Women ROBERT C.
More informationIntermediate Methods in Epidemiology Exercise No. 4 - Passive smoking and atherosclerosis
Intermediate Methods in Epidemiology 2008 Exercise No. 4 - Passive smoking and atherosclerosis The purpose of this exercise is to allow students to recapitulate issues discussed throughout the course which
More informationBMI and Contraception: What s the Evidence?
BMI and Contraception: What s the Evidence? Kathryn M. Curtis, PhD Division of Reproductive Health Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion
More informationConfounding Bias: Stratification
OUTLINE: Confounding- cont. Generalizability Reproducibility Effect modification Confounding Bias: Stratification Example 1: Association between place of residence & Chronic bronchitis Residence Chronic
More informationMain objective of Epidemiology. Statistical Inference. Statistical Inference: Example. Statistical Inference: Example
Main objective of Epidemiology Inference to a population Example: Treatment of hypertension: Research question (hypothesis): Is treatment A better than treatment B for patients with hypertension? Study
More informationJoseph W Hogan Brown University & AMPATH February 16, 2010
Joseph W Hogan Brown University & AMPATH February 16, 2010 Drinking and lung cancer Gender bias and graduate admissions AMPATH nutrition study Stratification and regression drinking and lung cancer graduate
More informationHealthy Montgomery Obesity Work Group Montgomery County Obesity Profile July 19, 2012
Healthy Montgomery Obesity Work Group Montgomery County Obesity Profile July 19, 2012 Prepared by: Rachel Simpson, BS Colleen Ryan Smith, MPH Ruth Martin, MPH, MBA Hawa Barry, BS Executive Summary Over
More informationSex Differences in Stroke Risk and Quality of Life after Stroke
Sex Differences in Stroke Risk and Quality of Life after Stroke Cheryl Bushnell, MD, MHS Associate Professor of Neurology Director, WFB Stroke Center Disclosures Research funding from: World Federation
More informationA n aly tical m e t h o d s
a A n aly tical m e t h o d s If I didn t go to the screening at Farmers Market I would not have known about my kidney problems. I am grateful to the whole staff. They were very professional. Thank you.
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationORIGINAL INVESTIGATION. Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease
ORIGINAL INVESTIGATION Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease Vicki A. Jackson, MD; Howard D. Sesso, ScD; Julie E. Buring, ScD; J. Michael Gaziano, MD Background:
More informationCopyright, 1995, by the Massachusetts Medical Society
Copyright, 1995, by the Massachusetts Medical Society Volume 332 JUNE 15, 1995 Number 24 THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST CANCER IN POSTMENOPAUSAL WOMEN GRAHAM A. COLDITZ, M.B.,
More informationCURRENT HORMONAL CONTRACEPTION - LIMITATIONS
CURRENT HORMONAL CONTRACEPTION - LIMITATIONS Oral Contraceptives - Features MERITS Up to 99.9% efficacy if used correctly and consistently Reversible method rapid return of fertility Offer non-contraceptive
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationSupplementary Online Content
Supplementary Online Content Li S, Chiuve SE, Flint A, et al. Better diet quality and decreased mortality among myocardial infarction survivors. JAMA Intern Med. Published online September 2, 2013. doi:10.1001/jamainternmed.2013.9768.
More informationThrombotic Stroke and Myocardial Infarction with Hormonal Contraception
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception Øjvind Lidegaard, Dr. Med. Sci., Ellen Løkkegaard, Ph.D.,
More informationYOUNG ADULT MEN AND MIDDLEaged
BRIEF REPORT Favorable Cardiovascular Profile in Young Women and Long-term of Cardiovascular and All-Cause Mortality Martha L. Daviglus, MD, PhD Jeremiah Stamler, MD Amber Pirzada, MD Lijing L. Yan, PhD,
More informationInvited Commentary Alcohol Consumption and Coronary Heart Disease: Good Habits May Be More Important Than Just Good Wine
American Journal of Epidemiology Copyright O 1996 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol 143, No 11 Printed in U.SA. Invited Commentary Alcohol Consumption
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationBiostatistics and Epidemiology Step 1 Sample Questions Set 1
Biostatistics and Epidemiology Step 1 Sample Questions Set 1 1. A study wishes to assess birth characteristics in a population. Which of the following variables describes the appropriate measurement scale
More informationBias. A systematic error (caused by the investigator or the subjects) that causes an incorrect (overor under-) estimate of an association.
Bias A systematic error (caused by the investigator or the subjects) that causes an incorrect (overor under-) estimate of an association. Here, random error is small, but systematic errors have led to
More informationReproductive Factors and Risk of Papillary Thyroid Cancer in Women
American Journal of Epidemiology Copyright O 2 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 5, Printed In USA. Reproductive Factors and Risk of Papillary
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationJUSTUS WARREN TASK FORCE MEETING DECEMBER 05, 2012
SAMUEL TCHWENKO, MD, MPH Epidemiologist, Heart Disease & Stroke Prevention Branch Chronic Disease & Injury Section; Division of Public Health NC Department of Health & Human Services JUSTUS WARREN TASK
More informationIn 1981, we published results from a case-control. study involving 881 cases and 863 controls. not associated with any substantial overall risk,
Br. J. Cancer (1986) 54, 825-832 Menopausal oestrogens and breast cancer risk: An expanded case-control study L.A. Brinton, R. Hoover & J.F. Fraumeni, Jr Environmental Epidemiology Branch, National Cancer
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright 2001 by the Massachusetts Medical Society VOLUME 345 D ECEMBER 20, 2001 NUMBER 25 ORAL CONTRACEPTIVES AND THE RISK OF MYOCARDIAL INFARCTION BEA C. TANIS, M.D.,
More informationEpidemiologic Measure of Association
Measures of Disease Occurrence: Epidemiologic Measure of Association Basic Concepts Confidence Interval for population characteristic: Disease Exposure Present Absent Total Yes A B N 1 = A+B No C D N 2
More informationIncidence of Surgically Treated Benign Prostatic Hypertrophy and of Prostate Cancer among Blacks and Whites in a Prepaid Health Care Plan
American Journal of EpKtermotogy Vo! 134, No 8 Copyright C 1991 by The Johns Hopkrts Uruversfty School of Hygiene and Put*: Health Printed in US A AS rights reserved A BRIEF ORIGINAL CONTRIBUTION Incidence
More informationANNALS of Internal Medicine
ANNALS of Internal Medicine AUGUST 1978 VOLUME 89 NUMBER 2 Published Monthly by the American College of Physicians Menopause and Coronary Heart Disease The Framingham Study TAVIA GORDON; WILLIAM B. KANNEL,
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationInfertility services reported by men in the United States: national survey data
MALE FACTOR Infertility services reported by men in the United States: national survey data John E. Anderson, Ph.D., Sherry L. Farr, Ph.D., M.S.P.H., Denise J. Jamieson, M.D., M.P.H., Lee Warner, Ph.D.,
More informationConfounding and Interaction
Confounding and Interaction Why did you do clinical research? To find a better diagnosis tool To determine risk factor of disease To identify prognosis factor To evaluate effectiveness of therapy To decide
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationShort-acting, inhaled 2-adrenergic receptor agonists
CLINICAL STUDIES Inhaled Beta-2 Adrenergic Receptor Agonists and Primary Cardiac Arrest Rozenn N. Lemaitre, PhD, David S. Siscovick, MD, PhD, Bruce M. Psaty, MD, PhD, Rachel M. Pearce, MS, Trivellore E.
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationSmoking categories. Men Former smokers. Current smokers Cigarettes smoked/d ( ) 0.9 ( )
Table 2.44. Case-control studies on smoking and colorectal Colon Rectal Colorectal Ji et al. (2002), Shanghai, China Cases were permanent Shanghai residents newly diagnosed at ages 30-74 years between
More informationGallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study
Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study Bette Liu, Valerie Beral, Angela Balkwill, Jane Green, Siân Sweetland,
More informationCardiovascular Disease
Cardiovascular Disease Chapter 15 Introduction Cardiovascular disease (CVD) is the leading cause of death in the U.S. One American dies from CVD every 33 seconds Nearly half of all Americans will die from
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationstudy of the effect of birth year
British Journal of Cancer (1997) 75(1), 139-143 1997 Cancer Research Campaign Oral contraceptive use at a young age and the risk of breast cancer: an Icelandic, population-based cohort study of the effect
More information